Table 4.

Non‐Hodgkin's lymphoma (NHL) HRs by time‐dependent statin use

		Age adjusted				Multivariable adjusted
	NHL cases	Hazard ratio	Lower CL	Upper CL	P‐value	Hazard ratio	Lower CL	Upper CL	P‐value
Statin use
No	660	1.00				1.00
Yes	53	0.82	0.68	1.00	0.05	0.81	0.66	1.00	0.04
Statin type
No statin use	660	1.00				1.00
Atorvastatin calcium	2	0.81	0.60	1.09	0.15	0.84	0.62	1.13	0.24
Fluvastatin sodium	6	0.66	0.31	1.38	0.27	0.58	0.26	1.31	0.19
Lovastatin	17	1.09	0.66	1.79	0.74	1.00	0.59	1.70	0.99
Pravastatin sodium	11	0.79	0.49	1.29	0.35	0.79	0.48	1.30	0.36
Simvastatin	15	0.88	0.62	1.24	0.46	0.85	0.59	1.22	0.37
Lipophilicity
No statin use	660	1.00				1.00
Lipophilic statin	40	0.84	0.68	1.04	0.11	0.83	0.66	1.03	0.09
Hydrophilic statin	11	0.77	0.50	1.21	0.26	0.76	0.49	1.22	0.28
Statin potency
No statin use	660	1.00				1.00
Low (Lovastatin, Fluvastatin)	23	0.89	0.58	1.35	0.57	0.81	0.52	1.26	0.34
Medium (Pravastatin)	11	0.78	0.48	1.26	0.30	0.77	0.47	1.27	0.31
High (Simvastatin, Atorvastatin)	17	0.83	0.65	1.04	0.11	0.83	0.65	1.06	0.13

Stratified by trial, WHI extension study, and age group.

Base model was adjusted by age.

Multivariable model adjusted for age, current medical care provider, history of lupus, history of rheumatoid arthritis.